FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Richard Pazdur

Research Profile

Activities & Behaviors

Drug Approval

Organizations

United States Food and Drug Administration

Chemicals & Drugs

Geographic Areas

United States

Procedures

Disorders

Concepts & Ideas

Co-author Network

Publications

TOP 3
Jenny J Zhang; Lijun Zhang; Huanyu Chen; Lori E Dodd; Anthony J Murgo; Richard Pazdur; Rajeshwari Sridhara
Assessment of audit methodologies for bias evaluation of tumor progression in oncology clinical trials.
Donna Przepiorka; Albert Deisseroth; Ann T Farrell; Edvardas Kaminskas; Robert Kane; Richard Pazdur
Gemtuzumab ozogamicin.
Michael Axelson; Zedong Dong; Kun He; Xiaoping Jiang; Patricia Keegan; Dubravka Kufrin; Ke Liu; Sarah Miksinski; Todd Palmby; Anne Marie Russell; Jian Wang; Hong Zhao; Richard Pazdur
U.s. Food and drug administration approval: vismodegib for recurrent, locally advanced, or metastatic Basal cell carcinoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Richard Pazdur (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jenny J Zhang; Lijun Zhang; Huanyu Chen; Lori E Dodd; Anthony J Murgo; Richard Pazdur; Rajeshwari Sridhara
Assessment of audit methodologies for bias evaluation of tumor progression in oncology clinical trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(10):2637-45.
2013: Donna Przepiorka; Albert Deisseroth; Ann T Farrell; Edvardas Kaminskas; Robert Kane; Richard Pazdur
Gemtuzumab ozogamicin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(13):1699-700.
2013: Michael Axelson; Zedong Dong; Kun He; Xiaoping Jiang; Patricia Keegan; Dubravka Kufrin; Ke Liu; Sarah Miksinski; Todd Palmby; Anne Marie Russell; Jian Wang; Hong Zhao; Richard Pazdur
U.s. Food and drug administration approval: vismodegib for recurrent, locally advanced, or metastatic Basal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(9):2289-93.
2013: Kristen M Snyder; Gregory Reaman; Debbie Avant; Richard Pazdur
The impact of the written request process on drug development in childhood cancer.
Pediatric blood & cancer 2013;60(4):531-7.
2013: Martin H Cohen; Chana Fuchs; Kun He; Patricia Keegan; Stacy Shord; Sharon Sickafuse; Hong Zhao; Huanyu Chen; Richard Pazdur
Approval summary: cetuximab in combination with Cisplatin or Carboplatin and 5-Fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer.
The oncologist 2013;18(4):460-6.
2012: R Angelo de Claro; Ann Farrell; Bahru Habtemariam; Edvardas Kaminskas; Robert Kane; Aakanksha Khandelwal; Kallappa Koti; Virginia Kwitkowski; Kyung Lee; Karen McGinn; Yanli Ouyang; Lara Akinsanya; Francisco Borrego; Janice Brown; Julie Bullock; Xiao Hong Chen; Kathleen Clouse; Mark Rothmann; Haleh Saber; Marjorie Shapiro; Richard Pazdur
U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(21):5845-9.
2012: Tatiana M Prowell; Richard Pazdur
Pathological complete response and accelerated drug approval in early breast cancer.
The New England journal of medicine 2012;366(26):2438-41.
2012: Albert Deisseroth; Ann Farrell; Christine Garnett; Joseph Grillo; Edvardas Kaminskas; Hong L Lu; Satjit Brar; Julie Bullock; Laurie B Burke; Wei Chen; Atiqur Rahman; Mark D Rothmann; Haleh Saber; R Sridhara; Jian Wang; Richard Pazdur
U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(12):3212-7.
2012: Patricia Cortazar; John Johnson; Robert Justice; Patricia Keegan; R Sridhara; Richard Pazdur
US Food and Drug Administration approval overview in metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(14):1705-11.
2012: Martha Donoghue; Joseph E Gootenberg; Kun He; Vaishali Jarral; Josephine M Jee; Patricia Keegan; Lori Kotch; Steven J Lemery; Richard T Lostritto; Anshu Marathe; Anne Pilaro; Stacy Shord; R Sridhara; Ying Wang; Weishi Yuan; Hong Zhao; Liang Zhou; William M Adams; Richard Pazdur
Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a "physician's choice" control arm in a randomized approval trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(6):1496-505.
2012: Thomas M Herndon; Xiaoping Jiang; Patricia Keegan; Martin H Cohen; Suzanne G Demko; Joseph E Gootenberg; Kun He; Richard Pazdur
U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma.
The oncologist 2012;17(10):1323-8.
2012: Gideon M Blumenthal; Patricia Cortazar; Robert Justice; Anthony Murgo; R Sridhara; Shenghui Tang; Jenny J Zhang; Richard Pazdur
FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors.
The oncologist 2012;17(8):1108-13.
2012: Martin H Cohen; John R Johnson; Robert Justice; Richard Pazdur
Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumors.
The oncologist 2012;17(7):992-7.
2011: Marc R Theoret; Jenny J Zhang; Robert Justice; Patricia Keegan; Yang-Min Ning; Richard Pazdur
The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.
The New England journal of medicine 2011;365(2):97-9.
2011: John R Johnson; Yang-Min Ning; Ann Farrell; Robert Justice; Patricia Keegan; Richard Pazdur
Accelerated approval of oncology products: the food and drug administration experience.
Journal of the National Cancer Institute 2011;103(8):636-44.
2011: Sandra J Casak; Steven J Lemery; Yuan Li Shen; Mark Rothmann; Aakanksha Khandelwal; Hong Zhao; Gina Davis; Vaishali Jarral; Patricia Keegan; Richard Pazdur
U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia.
The oncologist 2011;16(1):97-104.
2010: Shakun M Malik; Ke Liu; Xu Qiang; R Sridhara; Shenghui Tang; W David McGuinn; S Leigh Verbois; Anshu Marathe; Gene M Williams; Julie Bullock; Christoffer Tornoe; Sue Ching Lin; Terrance Ocheltree; Milinda Vialpando; Alice Kacuba; Robert Justice; Richard Pazdur
Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(20):4921-7.
2010: Steven J Lemery; Jenny Zhang; Mark D Rothmann; Jun Yang; Justin Earp; Hong Zhao; Andrew McDougal; Anne Pilaro; Raymond Chiang; Joseph E Gootenberg; Patricia Keegan; Richard Pazdur
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(17):4331-8.
2010: Min Lu; Martin H Cohen; Dwaine Rieves; Richard Pazdur
FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease.
American journal of hematology 2010;85(5):315-9.
2010: Martin H Cohen; Patricia Cortazar; Robert Justice; Richard Pazdur
Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC).
The oncologist 2010;15(12):1352-8.
2010: Martin H Cohen; John R Johnson; Somesh Chattopadhyay; Shenghui Tang; Robert Justice; R Sridhara; Richard Pazdur
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC).
The oncologist 2010;15(12):1344-51.
2010: Michael Brave; Ann Farrell; Sue Ching Lin; Terrance Ocheltree; Sarah Pope Miksinski; Shwu-Luan Lee; Haleh Saber; Jeanne Fourie; Christoffer Tornoe; Brian Booth; Weishi Yuan; Kun He; Robert Justice; Richard Pazdur
FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation.
Oncology 2010;78(3-4):282-8.
2010: Amy E McKee; Ann T Farrell; Richard Pazdur; Janet Woodcock
The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology.
The oncologist 2010;15 Suppl 1():13-8.
2010: Martin H Cohen; Patricia Cortazar; Robert Justice; Richard Pazdur
Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors.
The oncologist 2010;15(3):300-7.
2010: Jeff Summers; Martin H Cohen; Patricia Keegan; Richard Pazdur
FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma.
The oncologist 2010;15(1):104-11.
2009: Andrew Dmytrijuk; Kathy Robie-Suh; Dwaine Rieves; Richard Pazdur
Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
Oncology (Williston Park, N.Y.) 2009;23(13):1171-7.
2009: Martin H Cohen; Yuan Li Shen; Patricia Keegan; Richard Pazdur
FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
The oncologist 2009;14(11):1131-8.
2009: Martin H Cohen; Robert Justice; Richard Pazdur
Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer.
The oncologist 2009;14(9):930-5.
2009: Faranak Jamali; Steven Lemery; Kassa Ayalew; Suzanne Robottom; Kathy Robie-Suh; Dwaine Rieves; Richard Pazdur
Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
Oncology (Williston Park, N.Y.) 2009;23(8):704-9.
2009: Ruthann M Giusti; Martin H Cohen; Patricia Keegan; Richard Pazdur
FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer.
The oncologist 2009;14(3):284-90.
2009: Robert C Kane; Ann T Farrell; Rajanikanth Madabushi; Brian Booth; Somesh Chattopadhyay; R Sridhara; Robert Justice; Richard Pazdur
Sorafenib for the treatment of unresectable hepatocellular carcinoma.
The oncologist 2009;14(1):95-100.
2008: Ann T Farrell; Richard Pazdur; Andrew C von Eschenbach
Expediting the availability of drugs for US patients with cancer.
Nature clinical practice. Urology 2008;5(12):654-6.
2008: Maitreyee Hazarika; Edwin Rock; Gene Williams; Ramzi Dagher; R Sridhara; Brian Booth; Ann Farrell; Robert Justice; Richard Pazdur
Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy.
The oncologist 2008;13(10):1120-7.
2008: Qin Ryan; Amna Ibrahim; Martin H Cohen; John Johnson; Chia-wen Ko; R Sridhara; Robert Justice; Richard Pazdur
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.
The oncologist 2008;13(10):1114-9.
2008: Andrew Dmytrijuk; Kathy Robie-Suh; Martin H Cohen; Dwaine Rieves; Karen Weiss; Richard Pazdur
FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
The oncologist 2008;13(9):993-1000.
2008: Maitreyee Hazarika; Xiaoping Jiang; Qi Liu; Shwu-Luan Lee; Roshni P Ramchandani; Christine Garnett; Micheal S Orr; R Sridhara; Brian Booth; John K Leighton; William Timmer; Ravi Harapanhalli; Ramzi Dagher; Robert Justice; Richard Pazdur
Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(17):5325-31.
2008: Robert J Lechleider; Edvardas Kaminskas; Xiaoping Jiang; Robeena Aziz; Julie Bullock; Ravindra Kasliwal; Ravi Harapanhalli; Sarah Pope; R Sridhara; John Leighton; Brian Booth; Ramzi Dagher; Robert Justice; Richard Pazdur
Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(14):4378-84.
2008: Martin H Cohen; John R Johnson; Robert Justice; Richard Pazdur
FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
The oncologist 2008;13(6):709-14.
2008: Vinni Juneja; Patricia Keegan; Joseph E Gootenberg; Mark D Rothmann; Yuan Li Shen; Kyung Y Lee; Karen D Weiss; Richard Pazdur
Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3242-7.
2008: Robert C Kane; W David McGuinn; Ramzi Dagher; Robert Justice; Richard Pazdur
Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy.
The oncologist 2008;13(4):445-50.
2008: Ruthann M Giusti; Kaushikkumar Shastri; Anne M Pilaro; Chana Fuchs; Ruth Cordoba-Rodriguez; Kallappa Koti; Mark Rothmann; Angela Yuxin Men; Hong Zhao; Monica Hughes; Patricia Keegan; Karen D Weiss; Richard Pazdur
U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(5):1296-302.
2008: Suzanne Demko; Jeffrey Summers; Patricia Keegan; Richard Pazdur
FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia.
The oncologist 2008;13(2):167-74.
2008: Michael Brave; Vicki Goodman; Edvardas Kaminskas; Ann Farrell; William Timmer; Sarah Pope; Ravi Harapanhalli; Haleh Saber; David Morse; Julie Bullock; Angela Men; Carol Noory; Roshni P Ramchandani; Leslie Kenna; Brian Booth; Jogarao V S Gobburu; Xiaoping Jiang; R Sridhara; Robert Justice; Richard Pazdur
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(2):352-9.
2008: Richard Pazdur
Endpoints for assessing drug activity in clinical trials.
The oncologist 2008;13 Suppl 2():19-21.
2007: Adrian M Senderowicz; John R Johnson; R Sridhara; Paul Zimmerman; Robert Justice; Richard Pazdur
Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.
Oncology (Williston Park, N.Y.) 2007;21(14):1696-706; discussion 1706-9, 1712, 1715.
2007: Atiqur Rahman; Richard Pazdur; Yaning Wang; Shiew-Mei Huang; Lawrence Lesko
The value meal: effect of food on lapatinib bioavailability.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(33):5333-4; author reply 5334-5.
2007: Edwin P Rock; Dianne L Kennedy; Melissa H Furness; William F Pierce; Richard Pazdur; Laurie B Burke
Patient-reported outcomes supporting anticancer product approvals.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(32):5094-9.
2007: Yang-Min Ning; Kun He; Ramzi Dagher; R Sridhara; Ann T Farrell; Robert Justice; Richard Pazdur
Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma.
Oncology (Williston Park, N.Y.) 2007;21(12):1503-8; discussion 1511, 1513, 1516 passim.
2007: Robert C Bast; J Tate Thigpen; Arbuck Susan; Karen Basen-Engquist; Laurie B Burke; Ralph Freedman; Sandra J Horning; Robert F Ozols; Gordon J Rustin; David Spriggs; Lari Wenzel; Richard Pazdur
Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop.
Gynecologic oncology 2007;107(2):173-6.
2007: Bhupinder S Mann; John R Johnson; Martin H Cohen; Robert Justice; Richard Pazdur
FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
The oncologist 2007;12(10):1247-52.
2007: Robert C Kane; Ramzi Dagher; Ann Farrell; Chia-Wen Ko; R Sridhara; Robert Justice; Richard Pazdur
Bortezomib for the treatment of mantle cell lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 1):5291-4.
2007: Patricia Anne Dinndorf; Joe Gootenberg; Martin H Cohen; Patricia Keegan; Richard Pazdur
FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
The oncologist 2007;12(8):991-8.
2007: Kenneth C Anderson; Alison L Hannah; Richard Pazdur; Ann T Farrell
A strategic framework for novel drug development in multiple myeloma.
British journal of haematology 2007;138(2):153-9.
2007: Martin H Cohen; Joe Gootenberg; Patricia Keegan; Richard Pazdur
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
The oncologist 2007;12(6):713-8.
2007: Ruthann M Giusti; Kaushikkumar A Shastri; Martin H Cohen; Patricia Keegan; Richard Pazdur
FDA drug approval summary: panitumumab (Vectibix).
The oncologist 2007;12(5):577-83.
2007: Bhupinder S Mann; John R Johnson; Kun He; R Sridhara; Sophia Abraham; Brian P Booth; Leigh Verbois; David E Morse; Josephine M Jee; Sarah Pope; Ravi S Harapanhalli; Ramzi Dagher; Ann Farrell; Robert Justice; Richard Pazdur
Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(8):2318-22.
2007: Martin H Cohen; Joe Gootenberg; Patricia Keegan; Richard Pazdur
FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer.
The oncologist 2007;12(3):356-61.
2007: Vicki L Goodman; Edwin P Rock; Ramzi Dagher; Roshni P Ramchandani; Sophia Abraham; Jogarao V S Gobburu; Brian P Booth; S Leigh Verbois; David E Morse; Cheng Yi Liang; Nallaperumal Chidambaram; Janet X Jiang; Shenghui Tang; Kooros Mahjoob; Robert Justice; Richard Pazdur
Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(5):1367-73.
2007: Edwin P Rock; Jane A Scott; Dianne L Kennedy; R Sridhara; Richard Pazdur; Laurie B Burke
Challenges to use of health-related quality of life for Food and Drug Administration approval of anticancer products.
Journal of the National Cancer Institute. Monographs 2007;(37):27-30.
2007: Edwin P Rock; Vicki Goodman; Janet X Jiang; Kooros Mahjoob; S Leigh Verbois; David Morse; Ramzi Dagher; Robert Justice; Richard Pazdur
Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
The oncologist 2007;12(1):107-13.
2006: Robert C Kane; Ann T Farrell; Haleh Saber; Shenghui Tang; Gene Williams; Josephine M Jee; Chengyi Liang; Brian Booth; Nallaperumal Chidambaram; David Morse; R Sridhara; Patricia Garvey; Robert Justice; Richard Pazdur
Sorafenib for the treatment of advanced renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(24):7271-8.
2006: George Shashaty; Raymond Frankewich; Tamal Chakraborti; Jasti Choudary; Suliman Al-Fayoumi; Alice Kacuba; Sonia Castillo; Kathy Robie-Suh; Dwaine Rieves; Karen Weiss; Richard Pazdur
Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis.
Oncology (Williston Park, N.Y.) 2006;20(14):1799-1806, 1811; discussion 1811-13, 1817.
2006: Michael Brave; Ramzi Dagher; Ann Farrell; Sophia Abraham; Roshni P Ramchandani; Jogarao V S Gobburu; Brian Booth; Xiaoping Jiang; R Sridhara; Robert Justice; Richard Pazdur
Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer.
Oncology (Williston Park, N.Y.) 2006;20(11):1401-4, 1410; discussion 1410-11, 1415-6.
2006: Martin H Cohen; John R Johnson; Tristan Massie; R Sridhara; W David McGuinn; Sophia Abraham; Brian P Booth; M Anwar Goheer; David Morse; Xiao H Chen; Nallaperumal Chidambaram; Leslie Kenna; Jogarao V S Gobburu; Robert Justice; Richard Pazdur
Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(18):5329-35.
2006: Ann T Farrell; I Papadouli; A Hori; M Harczy; B Harrison; W Asakura; Michel Marty; Ramzi Dagher; Richard Pazdur
The advisory process for anticancer drug regulation: a global perspective.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(6):889-96.
2006: Robert C Kane; Ann T Farrell; R Sridhara; Richard Pazdur
United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(10):2955-60.
2006: Richard Pazdur
PROs: defining clinical benefit from the patient's perspective. Draft guidance provides direction in evaluating patient-reported outcomes.
Oncology (Williston Park, N.Y.) 2006;20(6):660.
2005: Martin H Cohen; John R Johnson; Richard Pazdur
Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 1):6767-71.
2005: Kenneth C Anderson; Richard Pazdur; Ann T Farrell
Development of effective new treatments for multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(28):7207-11.
2005: John R Johnson; Martin Cohen; R Sridhara; Yeh-Fong Chen; Gene M Williams; John Duan; Jogarao V S Gobburu; Brian Booth; Kimberly Benson; John Leighton; Li Shan Hsieh; Nallaperumal Chidambaram; Paul Zimmerman; Richard Pazdur
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(18):6414-21.
2005: Bhupinder S Mann; John R Johnson; Roswitha Kelly; R Sridhara; Grant Williams; Richard Pazdur
Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(16):5671-7.
2005: Richard Pazdur
The FDA's new oncology office.
Clinical advances in hematology & oncology : H&O 2005;3(8):612-3.
2005: Martin H Cohen; John R Johnson; Yeh-Fong Chen; R Sridhara; Richard Pazdur
FDA drug approval summary: erlotinib (Tarceva) tablets.
The oncologist 2005;10(7):461-6.
2005: Martin H Cohen; John R Johnson; Yong-Cheng Wang; R Sridhara; Richard Pazdur
FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer.
The oncologist 2005;10(6):363-8.
2005: Edvardas Kaminskas; Ann Farrell; Sophia Abraham; Amy Baird; Li-Shan Hsieh; Shwu-Luan Lee; John K Leighton; Hasmukh Patel; Atiqur Rahman; R Sridhara; Yong-Cheng Wang; Richard Pazdur
Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(10):3604-8.
2005: Edvardas Kaminskas; Ann T Farrell; Yong-Cheng Wang; R Sridhara; Richard Pazdur
FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
The oncologist 2005;10(3):176-82.
2005: Maitreyee Hazarika; Robert M White; Brian P Booth; Yong-Cheng Wang; Doo Y Lee Ham; Cheng Yi Liang; Atiqur Rahman; Jogarao V S Gobburu; Ning Li; R Sridhara; David E Morse; Richard T Lostritto; Patricia Garvey; John R Johnson; Richard Pazdur
Pemetrexed in malignant pleural mesothelioma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(3):982-92.
2005: Martin H Cohen; John R Johnson; Richard Pazdur
U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(1):12-9.
2004: Ramzi Dagher; Ning Li; Sophia Abraham; Atiqur Rahman; R Sridhara; Richard Pazdur
Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(24):8147-51.
2004: Lilia Talarico; Gang Chen; Richard Pazdur
Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(22):4626-31.
2004: Ramzi Dagher; John Johnson; Grant Williams; Patricia Keegan; Richard Pazdur
Accelerated approval of oncology products: a decade of experience.
Journal of the National Cancer Institute 2004;96(20):1500-9.
2004: Paulo M Hoff; Everardo D Saad; Richard Pazdur; Robert Wolff; Yvonne Lassere; Karla R Bogaard; James L Abbruzzese
Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer.
Investigational new drugs 2004;22(3):307-13.
2004: Peter F Bross; Robert Kane; Ann T Farrell; Sophia Abraham; Kimberly Benson; Margaret E Brower; Sean Bradley; Jogarao V S Gobburu; Anwar Goheer; Shwu-Luan Lee; John Leighton; Cheng Yi Liang; Richard T Lostritto; W David McGuinn; David E Morse; Atiqur Rahman; Lilliam A Rosario; S Leigh Verbois; Grant Williams; Yong-Cheng Wang; Richard Pazdur
Approval summary for bortezomib for injection in the treatment of multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 1):3954-64.
2004: Paulo M Hoff; Richard Pazdur; Yvonne Lassere; Susan Carter; Dvorit Samid; Diane Polito; James L Abbruzzese
Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(11):2078-83.
2004: Richard Pazdur
The Jim interview.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2004;52(4):217-9.
2004: Paulo M Hoff; Richard Pazdur
Progress in the development of novel treatments for colorectal cancer.
Oncology (Williston Park, N.Y.) 2004;18(6):705-8.
2004: Martin H Cohen; Grant A Williams; R Sridhara; Gang Chen; W David McGuinn; David Morse; Sophia Abraham; Atiqur Rahman; Chenyi Liang; Richard T Lostritto; Amy Baird; Richard Pazdur
United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(4):1212-8.
2004: Grant Williams; Richard Pazdur; Robert Temple
Assessing tumor-related signs and symptoms to support cancer drug approval.
Journal of biopharmaceutical statistics 2004;14(1):5-21.
2004: Maitreyee Hazarika; Robert M White; John R Johnson; Richard Pazdur
FDA drug approval summaries: pemetrexed (Alimta).
The oncologist 2004;9(5):482-8.
2004: Amna Ibrahim; Steven Hirschfeld; Martin H Cohen; Donna J Griebel; Grant A Williams; Richard Pazdur
FDA drug approval summaries: oxaliplatin.
The oncologist 2004;9(1):8-12.
2004: Melanie Royce; Eric K Rowinsky; Paulo M Hoff; John Coyle; Robert DeJager; Richard Pazdur; Leonard B Saltz
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum.
Investigational new drugs 2004;22(1):53-61.
2003: Peter F Bross; Amy Baird; Gang Chen; Josephine M Jee; Richard T Lostritto; David E Morse; Liliam A Rosario; Gene M Williams; Peiling Yang; Atiqur Rahman; Grant Williams; Richard Pazdur
Fulvestrant in postmenopausal women with advanced breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(12):4309-17.
2003: Amna Ibrahim; Nancy Scher; Grant Williams; R Sridhara; Ning Li; Gang Chen; John Leighton; Brian Booth; Jogarao V S Gobburu; Atiqur Rahman; Yung Hsieh; Rebecca Wood; Debra Vause; Richard Pazdur
Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(7):2394-9.
2003: John R Johnson; Peter Bross; Martin Cohen; Mark Rothmann; Gang Chen; Anne Zajicek; Jogarao V S Gobburu; Atiqur Rahman; Ann Staten; Richard Pazdur
Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(6):1972-9.
2003: Sunita Dwivedy Nasta; Paulo M Hoff; Christopher S George; Marcus Neubauer; Steven C Cohen; James L Abbruzzese; Rodger Winn; Richard Pazdur
Phase II study of MGI-114 administered intravenously for 5 days every 28 days to patients with metastatic colorectal cancer.
American journal of clinical oncology 2003;26(2):132-4.
2003: John R Johnson; Grant Williams; Richard Pazdur
End points and United States Food and Drug Administration approval of oncology drugs.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(7):1404-11.
2003: Steven Hirschfeld; Peter T C Ho; Malcolm Smith; Richard Pazdur
Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):1066-73.
2003: Robert C Kane; Peter F Bross; Ann T Farrell; Richard Pazdur
Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.
The oncologist 2003;8(6):508-13.
2003: Martin H Cohen; Grant A Williams; R Sridhara; Gang Chen; Richard Pazdur
FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.
The oncologist 2003;8(4):303-6.
2003: Paulo M Hoff; Everardo D Saad; Jaffer A Ajani; Yvonne Lassere; Cynthia Wenske; Diana Medgyesy; Sunita Dwivedy; Mark Russo; Richard Pazdur
Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):134-42.
2002: Everardo D Saad; Eric H Kraut; Paulo M Hoff; Dennis F Moore; Donnah Jones; Richard Pazdur; James L Abbruzzese
Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer.
American journal of clinical oncology 2002;25(5):451-3.
2002: Ramzi Dagher; Martin Cohen; Gene Williams; Mark Rothmann; Jogarao V S Gobburu; Gabriel Robbie; Atiqur Rahman; Gang Chen; Ann Staten; Donna Griebel; Richard Pazdur
Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(10):3034-8.
2002: Isagani M Chico; Richard Pazdur
Postmarketing re-evaluation of irinotecan plus 5-fluorouracil/leucovorin for first-line treatment of metastatic colorectal cancer.
Clinical colorectal cancer 2002;2(1):11-2.
2002: Steven Hirschfeld; Richard Pazdur
Oncology drug development: United States Food and Drug Administration perspective.
Critical reviews in oncology/hematology 2002;42(2):137-43.
2002: Martin H Cohen; Grant Williams; John R Johnson; John Duan; Jogarao V S Gobburu; Atiqur Rahman; Kimberly Benson; John Leighton; Sung K Kim; Rebecca Wood; Mark Rothmann; Gang Chen; Khin Maung U; Ann Staten; Richard Pazdur
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(5):935-42.
2002: Richard L Schilsky; Jeremey Levin; William H West; Alfred Wong; Bruce Colwell; Michael P Thirlwell; Rafat H Ansari; William N Bell; Robin L White; Barbara B Yates; Paul V McGuirt; Richard Pazdur
Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1519-26.
2002: Martin H Cohen; John R Johnson; Ning Li; Gang Chen; Richard Pazdur
Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(3):665-9.
2002: Peter F Bross; Martin H Cohen; Grant A Williams; Richard Pazdur
FDA drug approval summaries: fulvestrant.
The oncologist 2002;7(6):477-80.
2002: Martin H Cohen; Ramzi Dagher; Donna J Griebel; Amna Ibrahim; Alison Martin; Nancy S Scher; Gerald H Sokol; Grant A Williams; Richard Pazdur
U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.
The oncologist 2002;7(5):393-400.
2002: Martin H Cohen; Marie L Moses; Richard Pazdur
Gleevec for the treatment of chronic myelogenous leukemia: US. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status.
The oncologist 2002;7(5):390-2.
2001: Paulo M Hoff; Everardo D Saad; Farhad Ravandi-Kashani; E Czerny; Richard Pazdur
Phase I trial of i.v. administered tirapazamine plus cyclophosphamide.
Anti-cancer drugs 2001;12(6):499-503.
2001: Peter F Bross; J Beitz; Gang Chen; X H Chen; E Duffy; L Kieffer; S Roy; R Sridhara; Atiqur Rahman; Grant Williams; Richard Pazdur
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(6):1490-6.
2001: Nora Janjan; Christopher Crane; Barry W Feig; Karen Cleary; Ronelle A DuBrow; Steven A Curley; Jean-Nicolas Vauthey; P Lynch; Lee M Ellis; Robert Wolff; Renato Lenzi; James L Abbruzzese; Richard Pazdur; Paulo M Hoff; Pamela Allen; Thomas Brown; John M Skibber
Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer.
American journal of clinical oncology 2001;24(2):107-12.
2001: Melanie Royce; Paulo M Hoff; P Dumas; Yvonne Lassere; J Jack Lee; John Coyle; M P Ducharme; Robert L De Jager; Richard Pazdur
Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1493-500.
2001: Martin H Cohen; Steven Hirschfeld; S Flamm Honig; Amna Ibrahim; John R Johnson; J J O'Leary; Robert M White; Grant A Williams; Richard Pazdur
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
The oncologist 2001;6(1):4-11.
2000: Paulo M Hoff; J A Ellerton; Shaker R Dakhil; RJ Winn; James L Abbruzzese; Richard Pazdur
Phase II study of intravenous CI-958 in metastatic colorectal adenocarcinoma.
American journal of clinical oncology 2000;23(6):602-4.
2000: Melanie Royce; Diana Medgyesy; Thomas Zukowski; S Dwivedy; Paulo M Hoff; Richard Pazdur
Colorectal cancer: chemotherapy treatment overview.
Oncology (Williston Park, N.Y.) 2000;14(12 Suppl 14):40-6.
2000: Ritsuko Komaki; Nora Janjan; Jaffer A Ajani; Patrick M Lynch; JS Fairweather; Isaac Raijman; G R Blumenshein; Linus Ho; Peter W T Pisters; Barry W Feig; G L Walsh; Richard Pazdur
Phase I study of irinotecan and concurrent radiation therapy for upper GI tumors.
Oncology (Williston Park, N.Y.) 2000;14(12 Suppl 14):34-7.
2000: Paulo M Hoff; Nora Janjan; Everardo D Saad; John M Skibber; Christopher Crane; Yvonne Lassere; Karen R Cleary; S Benner; J Randolph; James L Abbruzzese; Richard Pazdur
Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(20):3529-34.
2000: Paulo M Hoff; Everardo D Saad; Nora Janjan; John M Skibber; Richard Pazdur
A phase I study. Preoperative UFT/leucovorin and radiation therapy in rectal cancer.
Oncology (Williston Park, N.Y.) 2000;14(10 Suppl 9):56-8.
2000: Melanie Royce; Paulo M Hoff; Richard Pazdur
Progress in colorectal cancer chemotherapy: how far have we come, how far to go?
Drugs & aging 2000;17(3):201-16.
2000: Nora Janjan; C N Crane; Barry W Feig; Karen Cleary; Ronelle A DuBrow; Steven A Curley; Lee M Ellis; Jean-Nicolas Vauthey; Renato Lenzi; P Lynch; Robert Wolff; Thomas Brown; Richard Pazdur; James L Abbruzzese; Paulo M Hoff; Pamela Allen; B Brown; John M Skibber
Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer.
International journal of radiation oncology, biology, physics 2000;47(3):713-8.
2000: Dah H Ho; W Covington; N Brown; S N Lin; Richard Pazdur; Y Y Huo; Patrick J Creaven; Youcef M Rustum; Neal J Meropol; Yvonne Lassere; Jun Kuritani; T Hayakawa
Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer.
Cancer chemotherapy and pharmacology 2000;46(5):351-6.
2000: Melanie Royce; Paulo M Hoff; Richard Pazdur
Novel oral chemotherapy agents.
Current oncology reports 2000;2(1):31-7.
2000: Steven Hirschfeld; A Shapiro; Ramzi Dagher; Richard Pazdur
Pediatric oncology: regulatory initiatives.
The oncologist 2000;5(6):441-4.
2000: Richard Pazdur
Recent advances in colorectal chemotherapy: oral fluorinated pyrimidines, oxaliplatin and irinotecan.
Journal of gastroenterology 2000;35 Suppl 12():131.
1999: Paulo M Hoff; Richard Pazdur
Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines: a novel class of oral antineoplastic agents.
Seminars in oncology 1999;26(6 Suppl 18):52-6.
1999: Paulo M Hoff; Melanie Royce; Diana Medgyesy; RA Brito; Richard Pazdur
Oral fluoropoyrimidines.
Seminars in oncology 1999;26(6):640-6.
1999: Robert A Newman; Jeri Kim; B M Newman; R Bruno; M Bayssas; M Klink-Alaki; Richard Pazdur
Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumors.
Anti-cancer drugs 1999;10(10):889-94.
1999: Melanie Royce; W McGarry; B Bready; Shaker R Dakhil; R J Belt; J Wendall Goodwin; R Gray; Paulo M Hoff; Rodger Winn; Richard Pazdur
Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(10):3276-82.
1999: Nora Janjan; Vincent S Khoo; James L Abbruzzese; Richard Pazdur; Ronelle A DuBrow; Karen R Cleary; Pamela K Allen; Patrick M Lynch; GA Glober; Robert Wolff; tyvin rich; John M Skibber
Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience.
International journal of radiation oncology, biology, physics 1999;44(5):1027-38.
1999: F Ravandi; Michael Rytting; C Osmon; E L Braud; R W Roach; K Edwards; Rodger Winn; James L Abbruzzese; Richard Pazdur
Phase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal cancer.
Anti-cancer drugs 1999;10(6):519-24.
1999: Paulo M Hoff; Yvonne Lassere; Richard Pazdur; Nora Janjan; Christopher Crane; John M Skibber
Preoperative UFT and calcium folinate and radiotherapy in rectal cancer.
Oncology (Williston Park, N.Y.) 1999;13(7 Suppl 3):129-31.
1999: Paulo M Hoff; Richard Pazdur
Oxaliplatin and UFT/oral calcium folinate for advanced colorectal carcinoma.
Oncology (Williston Park, N.Y.) 1999;13(7 Suppl 3):48-50.
1999: Richard Pazdur
Introduction. Beyond 5-fluorouracil.
Oncology (Williston Park, N.Y.) 1999;13(7 Suppl 3):15-6.
1999: RA Brito; Diana Medgyesy; Thomas Zukowski; Melanie Royce; Farhad Ravandi-Kashani; Paulo M Hoff; Richard Pazdur
Fluoropyrimidines: a critical evaluation.
Oncology 1999;57 Suppl 1():2-8.
1999: Nora Janjan; James L Abbruzzese; Richard Pazdur; Vincent S Khoo; Karen Cleary; Ronelle A DuBrow; J Ajani; tyvin rich; MS Goswitz; PA Evetts; Pamela K Allen; Patrick M Lynch; John M Skibber
Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1999;51(2):153-60.
1999: Richard Pazdur; Melanie Royce; Gladys I Rodriguez; David A Rinaldi; Yehuda Z Patt; Paulo M Hoff; Howard A Burris
Phase II trial of docetaxel for cholangiocarcinoma.
American journal of clinical oncology 1999;22(1):78-81.
1999: Paulo M Hoff; Yvonne Lassere; Richard Pazdur
Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil.
Drugs 1999;58 Suppl 3():77-83.
1998: Richard Pazdur; Paulo M Hoff; Diana Medgyesy; Melanie Royce; RA Brito
The oral fluorouracil prodrugs.
Oncology (Williston Park, N.Y.) 1998;12(10 Suppl 7):48-51.
1998: Jeri Kim; J Zhi; H Satoh; S G Koss-Twardy; Sandra Passe; I H Patel; Richard Pazdur
Pharmacokinetics of recombinant human interferon-alpha 2a combined with 5-fluorouracil in patients with advanced colorectal carcinoma.
Anti-cancer drugs 1998;9(8):689-96.
1998: Dah H Ho; Richard Pazdur; W Covington; N Brown; Y Y Huo; Yvonne Lassere; Jun Kuritani
Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(9):2085-8.
1998: Richard Pazdur
Irinotecan: toward clinical end points in drug development.
Oncology (Williston Park, N.Y.) 1998;12(8 Suppl 6):13-21.
1998: Paulo M Hoff; Richard Pazdur; Steven E Benner; R Canetta
UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
Anti-cancer drugs 1998;9(6):479-90.
1998: Jaffer A Ajani; JS Fairweather; P Dumas; Yehuda Z Patt; Richard Pazdur; P F Mansfield
Phase II study of Taxol in patients with advanced gastric carcinoma.
The cancer journal from Scientific American 1998;4(4):269-74.
1998: Richard Pazdur; Diana Medgyesy; RJ Winn; Shaker R Dakhil; D F Moore; A Scalzo; Paulo M Hoff; Arbuck Susan; James L Abbruzzese
Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma.
Investigational new drugs 1998;16(4):341-6.
1998: Jaffer A Ajani; Richard Pazdur; P Dumas; JS Fairweather
Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal carcinoma.
Investigational new drugs 1998;16(2):175-7.
1998: Richard Pazdur; Yvonne Lassere; EA Diaz-Canton; Dah H Ho
Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day schedule.
Cancer investigation 1998;16(3):145-51.
1997: Richard Pazdur; C Meyers; EA Diaz-Canton; James L Abbruzzese; Yehuda Z Patt; W Grove; Jaffer A Ajani
Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity.
American journal of clinical oncology 1997;20(6):573-6.
1997: EA Diaz-Canton; Richard Pazdur
Preoperative combined oral UFT plus leucovorin and radiation therapy for rectal cancer.
Oncology (Williston Park, N.Y.) 1997;11(9 Suppl 10):58-60.
1997: Richard Pazdur
Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin.
Oncology (Williston Park, N.Y.) 1997;11(9 Suppl 10):35-9.
1997: Richard Pazdur
UFT: East meets West in drug development.
Oncology (Williston Park, N.Y.) 1997;11(9 Suppl 10):11-3.
1997: Richard Pazdur; EA Diaz-Canton; W P Ballard; J E Bradof; S Graham; Arbuck Susan; James L Abbruzzese; Rodger Winn
Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(8):2905-9.
1997: Christina A Meyers; Andrzej P Kudelka; Charles A Conrad; C K Gelke; W Grove; Richard Pazdur
Neurotoxicity of CI-980, a novel mitotic inhibitor.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(3):419-22.
1997: EA Diaz-Canton; Richard Pazdur
Adjuvant medical therapy for colorectal cancer.
The Surgical clinics of North America 1997;77(1):211-28.
1997: Richard Pazdur; Yvonne Lassere; EA Diaz-Canton; B Bready; Dah H Ho
Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-day schedule.
Investigational new drugs 1997;15(2):123-8.
1997: Richard Pazdur
Phase II study of UFT plus leucovorin in colorectal cancer.
Oncology 1997;54 Suppl 1():19-23.
1996: Richard Pazdur; Yvonne Lassere; EA Diaz-Canton; B Bready; Dah H Ho
Phase I trials of uracil-tegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule-dependent toxicities.
Anti-cancer drugs 1996;7(7):728-33.
1996: N Touroutoglou; Richard Pazdur
Thymidylate synthase inhibitors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(2):227-43.
1996: Frank A Sinicrope; Richard Pazdur; Bernard Levin
Phase I trial of sulindac plus 5-fluorouracil and levamisole: potential adjuvant therapy for colon carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(1):37-41.
1996: Richard Pazdur; N J Meropol; E S Casper; C Fuchs; H O Douglass; mark vincent; James L Abbruzzese
Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer.
Investigational new drugs 1996;13(4):355-8.
1995: D F Moore; Richard Pazdur; S Sugarman; D Jones; Scott M Lippman; B Bready; James L Abbruzzese
Pilot phase II trial of 13-cis-retinoic acid and interferon-alpha combination therapy for advanced pancreatic adenocarcinoma.
American journal of clinical oncology 1995;18(6):525-7.
1995: J E Cortes; Richard Pazdur
Docetaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(10):2643-55.
1995: Richard Pazdur; B Bready; Jaffer A Ajani; James L Abbruzzese; A Markowitz; S Sugarman; D Jones; Bernard Levin
Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma.
American journal of clinical oncology 1995;18(5):436-8.
1994: Richard Pazdur; Yvonne Lassere; V Rhodes; Jaffer A Ajani; S M Sugarman; Yehuda Z Patt; D V Jones; A B Markowitz; James L Abbruzzese; B Bready
Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(11):2296-300.
1994: Richard Pazdur; D F Moore; B Bready; L Giannone; A Maldonado; Y G Lin; R H Fueger; RJ Winn; Bernard Levin
Phase II trial of edatrexate in patients with advanced hepatocellular carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(7):646-8.
1994: Jaffer A Ajani; David H Ilson; K Daugherty; Richard Pazdur; Patrick M Lynch; David P Kelsen
Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus.
Journal of the National Cancer Institute 1994;86(14):1086-91.
1994: Richard Pazdur; Yvonne Lassere; L T Soh; Jaffer A Ajani; B Bready; E Soo; S Sugarman; Yehuda Z Patt; James L Abbruzzese; Bernard Levin
Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(5):468-70.
1994: D F Moore; Richard Pazdur; James L Abbruzzese; Jaffer A Ajani; D W Dubovsky; James L Wade Iii; R J Belt; C Mangold; B Bready; RJ Winn
Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(3):286-7.
1994: Richard Pazdur; B Bready; A J Scalzo; J E Brandof; D R Close; S Kolbye; RJ Winn
Phase II trial of piroxantrone in metastatic gastric adenocarcinoma.
Investigational new drugs 1994;12(3):263-5.
1994: D F Moore; Richard Pazdur; James L Abbruzzese
Phase II trial of intravenous melphalan in advanced colorectal carcinoma.
Investigational new drugs 1994;12(2):133-6.
1993: I A Jaiyesimi; Richard Pazdur
Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal.
American journal of clinical oncology 1993;16(6):536-40.
1993: Yehuda Z Patt; Boris Yoffe; Chusilp Charnsangavej; Richard Pazdur; H Fischer; Karen Cleary; M Roh; Robert Smith; C A Noonan; Bernard Levin
Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b.
Cancer 1993;72(9):2574-82.
1993: Dah H Ho; Richard Pazdur; N S Brown; W P Covington; Martin N Raber; I H Krakoff
Clinical pharmacology of 11-acetyl-8-carbamoyloxymethyl-4-formyl-14-oxa-1,11-diazatetracyclo (7.4.1.0(2,7).0(10,12) tetradeca-2,4,6-trien-6,9-diyl diacetate (FK 973).
Anticancer research 1993;13(2):343-6.
1993: Richard Pazdur; Jaffer A Ajani; Yehuda Z Patt; J Gomez; B Bready; Bernard Levin
Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma.
Cancer 1993;71(4):1214-8.
1993: Jaffer A Ajani; Jack A Roth; M B Ryan; Joe B Putnam; Richard Pazdur; Bernard Levin; Jordan U Gutterman; M McMurtrey
Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(1):22-8.
1993: Richard Pazdur; B Bready; A Cangir
Pediatric hepatic tumors: clinical trials conducted in the United States.
Journal of surgical oncology. Supplement 1993;3():127-30.
1993: D Moore; Richard Pazdur
Systemic therapies for unresectable primary hepatic tumors.
Journal of surgical oncology. Supplement 1993;3():112-4.
1992: Richard Pazdur; Robert A Newman; B M Newman; A Fuentes; J Benvenuto; B Bready; D Moore; I Jaiyesimi; F Vreeland; M M Bayssas
Phase I trial of Taxotere: five-day schedule.
Journal of the National Cancer Institute 1992;84(23):1781-8.
1992: K P Hubbard; Richard Pazdur; Jaffer A Ajani; E Braud; A Blaustein; M King; M Llenado-Lee; Rodger Winn; Bernard Levin; James L Abbruzzese
Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer.
American journal of clinical oncology 1992;15(6):524-7.
1992: D F Moore; Richard Pazdur
Phase I study of 5-fluorouracil with folinic acid combined with recombinant human granulocyte-macrophage colony-stimulating factor.
American journal of clinical oncology 1992;15(6):464-6.
1992: D F Moore; Richard Pazdur; K Daugherty; P Tarassoff; James L Abbruzzese
Phase II study of gemcitabine in advanced colorectal adenocarcinoma.
Investigational new drugs 1992;10(4):323-5.
1992: Dah H Ho; W P Covington; Richard Pazdur; N S Brown; J Kuritani; Robert A Newman; Martin N Raber; I H Krakoff
Clinical pharmacology of combined oral uracil and ftorafur.
Drug metabolism and disposition: the biological fate of chemicals 1992;20(6):936-40.
1992: Richard Pazdur; J J Ajani; James L Abbruzzese; R J Belt; Shaker R Dakhil; D Dubovsky; S Graham; S Pilat; Rodger Winn; Bernard Levin
Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma.
Cancer 1992;70(8):2073-6.
1992: Richard Pazdur; D F Moore; B Bready
Modulation of fluorouracil with recombinant alfa interferon: M. D. Anderson Clinical trial.
Seminars in oncology 1992;19(2 Suppl 3):176-9.
1992: K P Hubbard; K Daugherty; Jaffer A Ajani; Richard Pazdur; Bernard Levin; James L Abbruzzese
Phase II trial of fazarabine in advanced colorectal carcinoma.
Investigational new drugs 1992;10(1):39-42.
1992: Richard Pazdur; Jaffer A Ajani; Rodger Winn; James Bearden; R J Belt; S Pilat; R Hallinan; Bernard Levin
A phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma.
Cancer 1992;69(4):878-82.
1991: Richard Pazdur; Dah H Ho; K Daugherty; W T Bradner; I H Krakoff; Martin N Raber
Phase I trial of FK973: description of a delayed vascular leak syndrome.
Investigational new drugs 1991;9(4):377-82.
1991: Jaffer A Ajani; Richard Pazdur; RJ Winn; James L Abbruzzese; Bernard Levin; R Belt; J Young; Yehuda Z Patt; I H Krakoff
Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas.
Investigational new drugs 1991;9(4):369-71.
1991: K Linke; Richard Pazdur; James L Abbruzzese; Jaffer A Ajani; Rodger Winn; J E Bradof; K Daugherty; Bernard Levin
Phase II study of amonafide in advanced pancreatic adenocarcinoma.
Investigational new drugs 1991;9(4):353-6.
1991: Richard Pazdur; B Bready; D F Moore
Clinical trials of fluorouracil with alpha-interferon in advanced colorectal carcinomas.
Seminars in oncology 1991;18(5 Suppl 7):67-70.
1991: Richard Pazdur
Fluorouracil and recombinant interferon alfa-2a in advanced gastrointestinal neoplasms.
British journal of haematology 1991;79 Suppl 1():56-9.
1991: Jaffer A Ajani; Richard Pazdur; RJ Winn; James L Abbruzzese; Bernard Levin; C Wiseman; M A Lenado-Lee; Yehuda Z Patt; I H Krakoff
Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma.
Investigational new drugs 1991;9(3):257-9.
1991: Richard Pazdur; D Jackson; B Shepherd; D Saddler; L Font; M McCardell; P Myers; S Schmidt
5-Fluorouracil and recombinant interferon alfa-2a: review of activity and toxicity in advanced colorectal carcinomas.
Oncology nursing forum 1991;18(1 Suppl):11-7.
1990: Richard Pazdur; Jaffer A Ajani; Yehuda Z Patt; Rodger Winn; D Jackson; B Shepard; R DuBrow; L Campos; M Quaraishi; J Faintuch
Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(12):2027-31.
1990: J Freimann; Richard Pazdur
Hepatic arterial embolization for treatment of glucagonomas: antineoplastic and palliative benefits.
American journal of clinical oncology 1990;13(3):271-5.
1989: Richard Pazdur
Adjuvant therapy for colon carcinoma.
American journal of clinical oncology 1989;12(6):537-40.